Vanguard Group’s Apimeds Pharmaceuticals US APUS Stock Holding History

Vanguard Group’s Portfolio APUS Stock Details APUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$96.7K	Hold	5,899	–	–	﹤0.01%	4182
2025 Q3	$105K	Buy	+5,899	New	+$109K	﹤0.01%	4223

Other funds holding APUS

HTHT

Hemenway Trust Hemenway Trust Salem, New Hampshire $1.43B AUM 37.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Vanguard Group's APUS Position: Q4 2025 in Review

Vanguard Group held its Apimeds Pharmaceuticals US (APUS) position steady in Q4 2025 at 5,899 shares worth $96.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4182.

Vanguard Group first reported a position in APUS in Q3 2025 and has held it in 2 quarters since. The position peaked at $105K in Q3 2025. 7 funds tracked by Wall St. Rank hold APUS as of Q4 2025.

Vanguard Group held 5,899 shares of Apimeds Pharmaceuticals US worth $96.7K as of Q4 2025.
Vanguard Group left its Apimeds Pharmaceuticals US share count unchanged in Q4 2025.
Apimeds Pharmaceuticals US made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4182 holding.
Vanguard Group first reported a position in Apimeds Pharmaceuticals US in Q3 2025 and has held it in 2 quarters since.
Vanguard Group's Apimeds Pharmaceuticals US position peaked at $105K in Q3 2025.
7 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.